Transferrin-conjugated doxorubicin-loaded PLGA nanoparticles with pH-responsive behavior: a synergistic approach for cancer therapy
Source abstract
Abstract
Doxorubicin (DOX) is an efficient chemotherapeutic agent widely used to treat different types of cancer; however, there is an inherent risk of adverse effects due to its unspecific action in healthy cells. In order to enhance the DOX arrival and accumulation inside the cancerous cells, we have developed DOX-loaded nanoparticles (NPs) using the biocompatible polymer poly(lactic-co-glycolic acid) (PLGA). pH sensitivity was achieved by incorporation of the surfactant, 77KS, while poloxamer was explored as stabilizer and chemosensitizer. The protein transferrin (Tf) was conjugated to the NPs with the role to actively targeting them to the cancerous cells. The nanoprecipitation method yielded NPs with size about 100 nm, with polydispersity index around 0.20 and a negative zeta potential. Transmission electron microscopy and infrared spectroscopy confirmed the shape and the functional groups presence. DOX release from the NPs followed a control and pH-sensitive pattern, allowing accelerated DOX release in acidic conditions. Through the hemolysis assay, using the erythrocyte as a model for the endosomal membrane, it was evidenced the pH-sensitive membranolytic behavior of the NPs. Furthermore, the NPs were safe and compatible with blood. Finally, the formulations were applied to tumor and non-tumor cell lines, HeLa and HaCaT, respectively. Over 72 h of incubation, the Tf-conjugated NPs induced a notable reduction in HeLa cell growth and were able to protect the HaCaT cells from the DOX unspecific cytotoxicity. The results suggest that the dual-active targeting promoted by 77KS and Tf is a promising platform to overcome the side effects of conventional chemotherapeutic drugs and nontargeted nanosystems.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. AbuHammad S, Zihlif M (2013) Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics 101:213–220. https://doi.org/10.1016/j.ygeno.2012.11.00910.1016/j.ygeno.2012.11.009 ↗
2. Baker EN, Baker HM, Kidd RD (2002) Lactoferrin and transferrin: functional variations on a common structural framework. Biochem Cell Biol 80:27–34. https://doi.org/10.1139/o01-15310.1139/o01-153 ↗
3. Balasubramanian S, Girija AR, Nagaoka Y, Iwai S, Suzuki M, Kizhikkilot V, Yoshida Y, Maekawa T, Nair SD (2013) Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int J Nanomedicine 9:437–459. https://doi.org/10.2147/IJN.S4988210.2147/IJN.S49882 ↗
4. Barenholz Y (2012) Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–134. https://doi.org/10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
5. Batrakova EV, Kabanov AV (2008) Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 130:98–106. https://doi.org/10.1016/j.jconrel.2008.04.01310.1016/j.jconrel.2008.04.013 ↗
6. Betancourt T, Brown B, Branon-Peppas L (2007) Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2:219–232. https://doi.org/10.2217/17435889.2.2.21910.2217/17435889.2.2.219 ↗
7. Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. https://doi.org/10.1006/abio.1976.999910.1006/abio.1976.9999 ↗
8. Chang J, Jallouli Y, Kroubi M, Yuan X, Feng W, Kang C, Pu P, Betbeder D (2009) Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. Int J Pharm 379:285–292. https://doi.org/10.1016/j.ijpharm.2009.04.03510.1016/j.ijpharm.2009.04.035 ↗
9. Chang J, Paillard A, Passirani C, Morille M, Benoit J, Betbeder D, Garcion E (2012) Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain Cancer cells. Pharm Res 29:1495–1505. https://doi.org/10.1007/s11095-011-0624-110.1007/s11095-011-0624-1 ↗
10. Chittasupho C, Lirdprapamongkol K, Kewsuwan P, Sarisuta N (2014) Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. Eur J Pharm Biopharm 88:529–538. https://doi.org/10.1016/j.ejpb.2014.06.02010.1016/j.ejpb.2014.06.020 ↗
11. Cryer AM, Thorley AJ (2019) Nanotechnology in the diagnosis and treatment of lung cancer. Pharm Ther, in press. https://doi.org/10.1016/j.pharmthera.2019.02.01010.1016/j.pharmthera.2019.02.010 ↗
12. Cui Y, Xu Q, Chow PK, Wang D, Wang C (2013) Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 34:8511–8520. https://doi.org/10.1016/j.biomaterials.2013.07.07510.1016/j.biomaterials.2013.07.075 ↗
13. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. https://doi.org/10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
14. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121:144–158. https://doi.org/10.1016/j.clim.2006.06.01010.1016/j.clim.2006.06.010 ↗
15. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1–R4. https://doi.org/10.1016/0378-5173(89)90281-010.1016/0378-5173(89)90281-0 ↗
16. Flatley M, Dodwell D (2019) Adjuvant treatment for breast cancer. Surgery (Oxford) 34:43–46. https://doi.org/10.1016/j.mpsur.2015.10.00310.1016/j.mpsur.2015.10.003 ↗
17. Fornaguera C, Calderó G, Mitjans M, Vinardell MP, Solansa C, Vauthier C (2015) Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. Nanoscale 7:6045–6059. https://doi.org/10.1039/c5nr00733j10.1039/c5nr00733j ↗
18. Frasco MF, Almeida GM, Santos-Silva F, Pereira M do C, Coelho MAN (2015).Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells. J Biomed Mater Res A103A:1476–1484. https://doi.org/10.1002/jbm.a.3528610.1002/jbm.a.35286 ↗
19. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741. https://doi.org/10.1016/s0006-2952(98)00307-410.1016/s0006-2952(98)00307-4 ↗
20. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38. https://doi.org/10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
21. He Y, Xing L, Cui P, Zhang J, Zhu Y, Qiao J, Lyu J, Zhang M, Luo C, Zhou Y, Lu N, Jiang H (2017) Transferrin-inspired vehicles based on pH-responsive coordination bond to combat multidrug-resistant breast cancer. Biomaterials 113:266–278. https://doi.org/10.1016/j.biomaterials.2016.11.00110.1016/j.biomaterials.2016.11.001 ↗
22. ICH – International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q2 R1: Guideline on Validation of Analytical Procedure – Methodology. (2005)
23. INVITOX PROTOCOL (1992) Number 37: red blood cell test system
24. Kumari M, Purohit MP, Patnaik S, Shukla Y, Kumar P, Gupta KC (2018) Curcumin loaded selenium nanoparticles synergize the anticancer potential of doxorubicin contained in self-assembled, cell receptor targeted nanoparticles. Eur J Pharm Biopharm 130:185–199. https://doi.org/10.1016/j.ejpb.2018.06.03010.1016/j.ejpb.2018.06.030 ↗
25. Lee ES, Oh KT, Kim D, Youn YS, Bae YH (2007) Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly (ethylene glycol)-b-poly(L-histidine). J Control Release 123:19–26. https://doi.org/10.1016/j.jconrel.2007.08.00610.1016/j.jconrel.2007.08.006 ↗
26. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S (2018) Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci 3:861–871. https://doi.org/10.1016/j.jacbts.2018.06.00510.1016/j.jacbts.2018.06.005 ↗
27. Macedo LB, Nogueira-Librelotto DR, Vargas J, Scheeren LE, Vinardell MP, Rolim CMB (2019) Poly (ɛ-Caprolactone) nanoparticles with pH-responsive behavior improved the In Vitro antitumor activity of methotrexate. AAPS PharmSciTech 20:165–177. https://doi.org/10.1208/s12249-019-1372-510.1208/s12249-019-1372-5 ↗
28. Malinovskaya Y, Melnikov P, Baklaushev V, Gabashvili A, Osipova N, Mantrov S, Ermolenko Y, Maksimenko O, Gorshkova M, Balabanyan V, Kreuter J, Gelperina S (2017) Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells. Int J Pharm 524:77–90. https://doi.org/10.1016/j.ijpharm.2017.03.04910.1016/j.ijpharm.2017.03.049 ↗
29. Montha W, Maneeprakorn W, Buatong N, Tang I-M, Pon-On W (2016) Synthesis of doxorubicin-PLGA loaded chitosan stabilized (Mn, Zn)Fe2O4 nanoparticles: biological activity and pH-responsive drug release. Mater Sci Eng C 59:235–240. https://doi.org/10.1016/j.msec.2015.09.09810.1016/j.msec.2015.09.098 ↗
30. Muhamad N, Plengsuriyakarn T, Na-Bangchang K (2018) Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine 13:3921–3935. https://doi.org/10.2147/IJN.S16521010.2147/IJN.S165210 ↗
31. Neun BW, Dobrovolskaia MA (2010) Method for in vitro analysis of nanoparticle thrombogenic properties. Characterization of Nanoparticles Intended for Drug Delivery. Methods Mol Biol 697 chapter 24
32. Nogueira DR, Mitjans M, Infante MR, Vinardell MP (2011a) The role of counterions in the membrane-disruptive properties of pH-sensitive lysine-based surfactants. Acta Biomater 7:2846–2856. https://doi.org/10.1016/j.actbio.2011.03.01710.1016/j.actbio.2011.03.017 ↗
33. Nogueira DR, Mitjans M, Infante MR, Vinardell MP (2011b) Comparative sensitivity of tumor and non-tumor cell lines as a reliable approach for in vitro cytotoxicity screening of lysine-based surfactants with potential pharmaceutical applications. Int J Pharm 420:51–58. https://doi.org/10.1016/j.ijpharm.2011.08.02010.1016/j.ijpharm.2011.08.020 ↗
34. Nogueira DR, Tavano L, Mitjans M, Pérez L, Infante MR, Vinardell MP (2013) In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials 34:2758–2772. https://doi.org/10.1016/j.biomaterials.2013.01.00510.1016/j.biomaterials.2013.01.005 ↗
35. Nogueira DR, Scheeren LE, Vinardell MP, Mitjans M, Infante MR, Rolim CMB (2015) Nanoparticles incorporating pH-responsive surfactants as a viable approach to improve the intracellular drug delivery. Mater Sci Eng C 57:100–106. https://doi.org/10.1016/j.msec.2015.07.03610.1016/j.msec.2015.07.036 ↗
36. Nogueira DR, Scheeren LE, Macedo LB, Marcolino AIP, Vinardell MP, Mitjans M, Infante MR, Farooqi A, Rolim CMB (2016) Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy. Amino Acids 48:157–168. https://doi.org/10.1007/s00726-015-2075-110.1007/s00726-015-2075-1 ↗
37. Nogueira-Librelotto DR, Scheeren LE, Vinardell MP, Mitjans M, Rolim CMB (2016) Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin. Colloid Surface B 147:326–335. https://doi.org/10.1016/j.colsurfb.2016.08.01410.1016/j.colsurfb.2016.08.014 ↗
38. Nogueira-Librelotto DR, Codevilla CF, Farooqi A, Rolim CMB (2017) Transferrin-conjugated Nanocarriers as active-targeted drug delivery platforms for cancer therapy. Cur Pharm Des 23:454–466. https://doi.org/10.2174/138161282266616102616234710.2174/1381612822666161026162347 ↗
39. Nothnagel L, Wacker MG (2018) How to measure release from nanosized carriers? Eur J Pharm Sci 120:199–211. https://doi.org/10.1016/j.ejps.2018.05.00410.1016/j.ejps.2018.05.004 ↗
40. Pandey SK, Patel DK, Maurya AK, Thakur R, Mishra DP, Vinayak M, Haldar C, Maiti P (2016) Controlled release of drug and better bioavailability using poly(lacticacid-co-glycolic acid) nanoparticles. Int J Biol Macromol:8999–8110. https://doi.org/10.1016/j.ijbiomac.2016.04.06510.1016/j.ijbiomac.2016.04.065 ↗
41. Pereverzeva E, Treschalin I, Treschalin M, Arantseva D, Ermolenko Y, Kumskova N, Maksimenko O, Balabanyan V, Kreuter J, Gelperina S (2019) Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. Int J Pharm 554:161–178. https://doi.org/10.1016/j.ijpharm.2018.11.01410.1016/j.ijpharm.2018.11.014 ↗
42. Pillai GJ, Greeshma MM, Menon D (2015) Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions. Colloid Surface B 136:1058–1066. https://doi.org/10.1016/j.colsurfb.2015.10.04710.1016/j.colsurfb.2015.10.047 ↗
43. Ritger PL, Peppas NA (1987) A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 5:23–36. https://doi.org/10.1016/0168-3659(87)90034-410.1016/0168-3659(87)90034-4 ↗
44. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of tranferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2:373–383. https://doi.org/10.1021/mp050032z10.1021/mp050032z ↗
45. Sanchez L, Mitjans M, Infante MR, Vinardell MP (2006a) Potential irritation of lysine derivative surfactants by hemolysis and HaCaT cell viability. Toxicol Lett 161:53–60. https://doi.org/10.1016/j.toxlet.2005.07.01510.1016/j.toxlet.2005.07.015 ↗
46. Sanchez L, Mitjans M, Infante MR, Vinardell MP (2006b) Determination of interleukin-1in human NCTC 2544 keratinocyte cells as a predictor of skin irritation from lysine-based surfactants. Toxicol Lett 167:40–46. https://doi.org/10.1016/j.toxlet.2006.08.00610.1016/j.toxlet.2006.08.006 ↗
47. Scheeren LE, Nogueira DR, Macedo LB, Vinardell MP, Mitjans M, Infante MR, Rolim CMB (2016) PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release. Colloid Surface B 138:117–127. https://doi.org/10.1016/j.colsurfb.2015.11.04910.1016/j.colsurfb.2015.11.049 ↗
48. Scheeren LE, Nogueira DR, Fernandes JR, Marcolino AIP, Macedo LB, Vinardell MP, Rolim CMB (2017) Comparative study of reversed-phase high-performance liquid chromatography and ultraviolet–visible spectrophotometry to determine doxorubicin in pH-sensitive nanoparticles. Anal Lett 51:1445–1463. https://doi.org/10.1080/00032719.2017.138003410.1080/00032719.2017.1380034 ↗
49. Sharma S, Parmar A, Kori S, Sandhir R (2016) PLGA-based nanoparticles: a new paradigm in biomedical applications. Trends Anal Chem 80:30–40. https://doi.org/10.1016/j.trac.2015.06.01410.1016/j.trac.2015.06.014 ↗
50. Shen ZM, Yang JT, Feng Y, Wu CC (1992) Conformational stability of porcine serum transferrin. Prot Sci I:1477–1484. https://doi.org/10.1002/pro.556001110910.1002/pro.5560011109 ↗
51. Shindelman JE, Ortmeyer AE, Sussman HH (1981) Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27:329–334. https://doi.org/10.1002/ijc.291027031110.1002/ijc.2910270311 ↗
52. Singhal JP, Ray AR (2002) Synthesis of blood compatible polyamide block copolymers. Biomaterials 23:1139–1145. https://doi.org/10.1016/S0142-9612(01)00228-910.1016/S0142-9612(01)00228-9 ↗
53. Soe ZC, Kwon JB, Thapa RK, Ou W, Nguyen HT, Gautam M, Oh KT, Choi H, Ku SK, Yong CS, Kim JO (2019) Transferrin-conjugated polymeric nanoparticle for receptor-mediated delivery of doxorubicin in doxorubicin-resistant breast cancer cells. Pharmaceutics 11:63–80. https://doi.org/10.3390/pharmaceutics1102006310.3390/pharmaceutics11020063 ↗
54. Sriraman SK, Salzano G, Sarisozen C, Torchilin V (2016) Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. Eur J Pharm Biopharm 105:40–49. https://doi.org/10.1016/j.ejpb.2016.05.02310.1016/j.ejpb.2016.05.023 ↗
55. Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M (2018) Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater 73:38–51. https://doi.org/10.1016/j.actbio.2018.04.00610.1016/j.actbio.2018.04.006 ↗
56. Tavano L, Aiello R, Ioele G, Picci N, Muzzalupo R (2014) Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties. Colloid Surface B 118:7–13. https://doi.org/10.1016/j.colsurfb.2014.03.01610.1016/j.colsurfb.2014.03.016 ↗
57. Tewes F, Munnier E, Antoon B, Okassa LN, Cohen-Jonathan S, Marchais H, Douziech-Eyrolles L, Souce M, Dubois P, Chourpa I (2007) Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm 66:488–492. https://doi.org/10.1016/j.ejpb.2007.02.01610.1016/j.ejpb.2007.02.016 ↗
58. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440–446. https://doi.org/10.1097/FPC.0b013e32833ffb5610.1097/FPC.0b013e32833ffb56 ↗
59. Tian L, Bae YH (2012) Cancer nanomedicines targeting tumor extracellular pH. Colloid Surface B 99:116–126. https://doi.org/10.1016/j.colsurfb.2011.10.03910.1016/j.colsurfb.2011.10.039 ↗
60. Tsuji T, Yoshitomi Y, Usukura J (2013) Endocytic mechanism of transferrin-conjugated nanoparticles and the effects of their size and ligand number on the efficiency of drug delivery. Microscopy 62:341–352. https://doi.org/10.1093/jmicro/dfs08010.1093/jmicro/dfs080 ↗
61. Vives MA, Infante MR, Garcia E, Selve C, Maugras M, Vinardell MP (1999) Erythrocyte hemolysis and shape changes induced by new lysine-derivate surfactants. Chem-Biol Interac 118:1–18. https://doi.org/10.1016/s0009-2797(98)00111-210.1016/s0009-2797(98)00111-2 ↗
62. Wang H, Zhao Y, Wang H, Gong J, He H, Shin MC, Yang VC, Huang Y (2014) Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J Control Release 192:47–56. https://doi.org/10.1016/j.jconrel.2014.06.05110.1016/j.jconrel.2014.06.051 ↗
63. Zhang X, Li J, Yan M (2016) Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Drug Dev Ind Pharm 40:1590–1599. https://doi.org/10.3109/03639045.2016.116010310.3109/03639045.2016.1160103 ↗